Readmission rates following surgeries in U.S. hospitals

Nearly 6 percent of people who underwent surgery were readmitted within 30 days, according to an analysis of U.S. hospitals. Results were recently published in JAMA [2015;313(5):483-495].

The authors mentioned that hospitals are being penalized if patients return after getting released, leading hospitals to pay closer attention to their readmittance rates.

This study examined 346 hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program between January 1, 2012, and December 31, 2012. The researchers evaluated surgical procedures as well as bariatric procedures, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral hernia repair and lower extremity vascular bypass.

Of the 498,875 operations performed in the hospitals, 5.7 percent resulted in unplanned re-admissions within 30 days of discharge. The readmission rate was highest in patients undergoing lower extremity vascular bypass (14.9 percent) and lowest for patients undergoing hysterectomy (3.8 percent). The most common reason for an unplanned readmission was surgical site infection, which occurred in 19.5 percent of readmissions.

“Readmissions after surgery were associated with new postdischarge complications related to the procedure and not exacerbation of prior index hospitalization complications, suggesting that readmissions after surgery are a measure of postdischarge complications,” the researchers wrote. “These data should be considered when developing quality indicators and any policies penalizing hospitals for surgical readmission.”

Read the JAMA article.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.